Biotech: Page 48
-
Danielle Ternes/BioPharma Dive
JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job
The chip maker struck a new deal with Amgen last Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.
By Gwendolyn Wu , Delilah Alvarado , Ben Fidler • Jan. 8, 2024 -
Getty Images
Year of biotech layoffs leaves industry looking for spark
Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive. However, recent deal and stock market momentum have brought some optimism.
By Delilah Alvarado , Ned Pagliarulo • Jan. 8, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
5 questions facing emerging biotech in 2024
An unusual FTC challenge could have implications for startups, while industry watchers gauge whether the sector’s recent momentum will end a lengthy funding crunch.
By Gwendolyn Wu • Jan. 8, 2024 -
Permission granted by Ionis Pharmaceuticals and Metagenomi
Gene editing startup Metagenomi files for an IPO
The Emeryville, California-based gene therapy developer has several preclinical programs in development with Moderna, Ionis and Affini-T.
By Gwendolyn Wu • Jan. 6, 2024 -
Getty Images
An unusual drugmaker raises north of $100M for ecstasy-based PTSD therapy
Lykos Therapeutics, formerly known as MAPS Public Benefit Corp., recently submitted its MDMA capsules for FDA approval, following two positive studies.
By Jacob Bell • Jan. 5, 2024 -
Courtesy of Intellia Therapeutics
Intellia to lay off staff, cut some early research
The CRISPR specialist joins some of its genetic medicine peers in trimming staff, announcing an “organizational streamlining” to focus resources on prioritiy drug programs.
By Gwendolyn Wu • Jan. 4, 2024 -
Getty Images
Allogene to shift strategy in bid to reposition CAR-T
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
By Ben Fidler • Jan. 4, 2024 -
Getty Images
Novo taps Flagship startups to develop drugs for obesity, MASH
The research deals with Omega Therapeutics and Cellarity are the first under a broad alliance Novo struck with Flagship last spring.
By Kristin Jensen • Jan. 4, 2024 -
Permission granted by Erin Beach/Moonwalk Biosciences
A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome
Moonwalk Biosciences, the latest biotech co-founded by Zhang, joins other startups aiming to alter gene expression without changing DNA.
By Gwendolyn Wu • Jan. 4, 2024 -
Michael M. Santiago via Getty Images
Goldman Sachs gets into biotech investing with new venture fund
The $650 million fund exceeded Goldman’s target and comes amid cautious optimism that biotech could rebound from a lengthy downturn.
By Kristin Jensen • Jan. 3, 2024 -
Getty Images
Roche joins startup Remix in bet on another way to drug RNA
The deal is the third Roche has formed with startups developing pills that target RNA, following similar pacts with Arrakis and Ribometrix.
By Ben Fidler • Jan. 3, 2024 -
Getty Images
Tome acquires startup Replace, gaining new genome editing tools
The deal is the second startup sale engineered by University of California, Berkeley scientist Shakked Halperin, and gives Tome a way to insert or delete small DNA sequences into the genome.
By Ben Fidler • Jan. 2, 2024 -
Sara Silbiger via Getty Images
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
The clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam.
By Ben Fidler • Dec. 22, 2023 -
Getty Images
Clene says its ALS drug data is not yet enough for FDA
The agency said initial trial evidence wouldn’t support an accelerated approval, according to the company, which plans to provide more data next year.
By Jacob Bell • Dec. 21, 2023 -
Mario Tama via Getty Images
J&J bets bigger on MeiraGTx’s eye gene therapy
Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.
By Jonathan Gardner • Dec. 21, 2023 -
Courtesy of BioMarin Pharmaceutical
BioMarin strikes deal with Elliott, agrees to review business
Under pressure from the activist investor, BioMarin will add more independent directors and set up an operational review committee.
By Kristin Jensen • Dec. 21, 2023 -
Getty Images
Argenx autoimmune drug study fails in blow to expansion hopes
The Dutch biotech’s star product has lost some luster after a second failed Phase 3 trial in two months, this time for a skin condition called pemphigus.
By Kristin Jensen • Dec. 20, 2023 -
Permission granted by Biogen
Biogen holds onto Tecfidera market in Europe for a little longer
A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.
By Ned Pagliarulo • Dec. 19, 2023 -
Getty Images
Point radiopharma drug results disappoint in prostate cancer study
While the study met its goal, the drug’s benefit was less than analysts had predicted, an outcome that could hasten a planned takeover by Eli Lilly.
By Ned Pagliarulo • Dec. 18, 2023 -
Getty Images
Structure shares sink as obesity pill misses expectations in small study
Results from a Phase 2 trial fell short of what’s been seen with a similar Eli Lilly medicine, causing the closely watched biotech’s shares to plummet.
By Ben Fidler • Dec. 18, 2023 -
Getty Images
Pivotal Life Sciences reloads with $389M, hunting for deals in a downturn
The firm is tracking startups that launched during the biotechnology sector’s peak a few years ago but now need fresh funds to move their programs forward, one of its investors said.
By Gwendolyn Wu • Dec. 18, 2023 -
Carl Court via Getty Images
European regulators push Biogen, CRISPR drugs toward approval
While a positive recommendation for the gene editing treatment Casgevy was expected, a clearance for Biogen’s Skyclarys has been no sure bet.
By Ben Fidler • Dec. 15, 2023 -
Getty Images
Vir to lay off staff, cut costs amid setbacks building on COVID success
The biotech is letting go of 75 employees and closing two R&D facilities, continuing a strategic reset under new CEO Marianne de Backer.
By Delilah Alvarado • Dec. 14, 2023 -
Courtesy of Apellis Pharmaceuticals
Apellis eye drug likely to be rejected in Europe, company says
According to Apellis executives, reviewers in Europe are skeptical of the benefits of its geographic atrophy medicine, Syfovre, and appear poised to recommend against approval at a meeting next month.
By Ben Fidler • Dec. 14, 2023 -
Permission granted by Bristol-Myers Squibb
Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree
The lucrative alliance, potentially worth more than $8 billion, continues a run of dealmaking for a class of cancer drugs that’s surged in popularity in recent years.
By Ben Fidler • Dec. 12, 2023
Previous
